Advancement in diabetes management with co-formulation insulin analog

Abstract

In routine, insulin initiation is often delayed in patients with uncontrolled diabetes mellitus due to clinical concerns like hypoglycaemia, weight gain and fear of injections. Convenient and flexible options are required to overcome these barriers. Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (a basal insulin) and insulin aspart (a prandial insulin). It is a novel treatment option to address both FPG and PPG in one device with ultra-long-acting basal Ideg and rapid acting IAsp. Several studies including RCTs and real world studies (BOOST, ARISE, etc) showed that this co-formulation is effective and safe (lower hypoglycemia and weight gain) as well as it provides flexibility, reduces insulin dose and pricking. In a nutshell, early initiation of insulin therapy is needed to avoid the effects of prolonged glycemic burden and alter the course of disease progression Premix/co-formulation Insulin is the preferred choice as per country guideline considering the clinical trial date and real-world evidence.

Keywords: Insulin co-formulation, Degludec, Aspart